secwatch / observer

Material Agreements

Entry into or termination of material definitive agreements (Items 1.01/1.02).

8-K items 1.01, 1.02 JSON
NTLA Intellia Therapeutics, Inc.

Intellia Therapeutics, Inc. terminated Factor IX Co-Development and Co-Funding Agreement with Regeneron Pharmaceuticals, Inc. (effective 2024-03-19).

“On March 19, 2024, Intellia Therapeutics, Inc. (the “Company” or “Intellia”) notified Regeneron Pharmaceuticals, Inc. (“Regeneron”) that the Company is opting out of its Factor IX Co-Development and Co-Funding Agreement (the “Co-Co Agreement”), which the Company and Regeneron entered into in May 2020.”
XAIR Beyond Air, Inc.

Beyond Air, Inc. entered into Placement Agency Agreement with Roth Capital Partners, LLC and Laidlaw & Company (UK) Ltd. valued at co-placement agents; 7% cash fee of aggregate gross proceeds (effective 2024-03-20).

“On March 20, 2024, the Company also entered into a placement agency agreement (the “Placement Agency Agreement”) with Roth Capital Partners, LLC and Laidlaw & Company (UK) Ltd. (the “Co-Placement Agents”) as the co-placement agents in connection with the offering.”
XAIR Beyond Air, Inc.

Beyond Air, Inc. entered into Securities Purchase Agreement with certain institutional and accredited investors valued at 9,638,556 shares of common stock and warrants, offering price $1.66 per unit (effective 2022-03-20).

“On March 20, 2022, Beyond Air, Inc., a Delaware corporation (the “Company”), entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain institutional and accredited investors”
AREB AMERICAN REBEL HOLDINGS INC

AMERICAN REBEL HOLDINGS INC entered into Securities Purchase Agreement with 1800 Diagonal Lending, LLC valued at $235,750 (effective 2024-03-21).

“On March 21, 2024, the Company entered into a Securities Purchase Agreement with 1800 Diagonal Lending, LLC, an accredited investor (“the Lender”), pursuant to which the Lender made a loan to the Company, evidenced by a promissory note in the principal amount of $235,750 (the “Note”).”
Summit Midstream Partners, LP

Summit Midstream Partners, LP amended Fourth Amendment to Loan and Security Agreement with Bank of America, N.A. valued at amended the revolving credit facility to permit the Transaction, amend change of control, permit cer (effective 2024-03-22).

“In connection with the closing of the Transaction, Summit Midstream Holdings, LLC, a Delaware limited liability company (“Holdings”), entered into that certain Fourth Amendment to Loan and Security Agreement (the “ABL Amendment”) by and among Summit, Holdings, the subsidiaries of Holdings party thereto, as subsidiary guarantors, and Bank of America, N.A., as administrative agent (“Agent”), pursuant to which Holdings amended its revolving credit facility governed by that certain Loan and Security Agreement dated as of November 2, 2021 (as amended, restated, supplemented or otherwise modified prior to the date hereof, the “Credit Agreement” and the Credit Agreement, as amended by the ABL Amendment, the “Amended Credit Agreement”) by and among Summit, as parent guarantor, Holdings, as borrower, the subsidiaries of Holdings party thereto, as subsidiary guarantors, the lenders party thereto from time to time and Agent.”
Summit Midstream Partners, LP

Summit Midstream Partners, LP entered into Purchase and Sale Agreement with MPLX LP valued at cash consideration of $625.0 million (effective 2024-03-22).

“On March 22, 2024, Summit Midstream Partners, LP (NYSE: SMLP), a Delaware limited partnership (“Summit” or the “Partnership”) and Summit Midstream Opco, LP, a Delaware limited partnership (“OpCo”) and an indirectly owned subsidiary of Summit, completed the sale of Summit Midstream Utica, LLC, a Delaware limited liability company (“Utica”), to a subsidiary of MPLX LP (NYSE: MPLX), a Delaware limited partnership (“MPLX”), for cash consideration of $625.0 million, subject to customary post-closing adjustments (the “Transaction”), pursuant to a Purchase and Sale Agreement, dated March 22, 2024 (the “Purchase Agreement”), by and among OpCo, as Seller, MPLX, as Buyer, and solely for purposes of Section 12.18 thereto, Summit, as Seller Parent (each as defined therein).”
GTCH GBT Technologies Inc.

GBT Technologies Inc. terminated Patent Purchase Agreement with Bannix Acquisition Corp. with Bannix Acquisition Corp. (effective 2024-03-19).

“As the PPA was contingent upon Bannix closing the acquisition of the EVIE and due to the BNIX EVIE Termination Letter, on March 19, 2024 Bannix and Tokenize agreed to terminate the PPA which was consented to by the Company”
GTCH GBT Technologies Inc.

GBT Technologies Inc. entered into Patent Purchase Agreement with VisionWave Technologies Inc. valued at $30,000,000 (effective 2024-03-19).

“Effective as of March 19, 2024, GBT Tokenize Corp. (“Tokenize”), which is 50% owned by GBT Technologies Inc. (the “Company”) entered into a Patent Purchase Agreement with VisionWave Technologies Inc. (“ VisionWave”) pursuant to which VisionWave agreed to acquire from Tokenize the entire right, title, and interest of certain patents and patent applications providing an intellectual property basis for a machine learning driven technology that controls radio wave transmissions, analyzes their reflections data, and constructs 2D/3D images of stationary and in motion objects (“VisionWave PPA”).”
SMCI Super Micro Computer, Inc.

Super Micro Computer, Inc. entered into Underwriting Agreement with Goldman Sachs & Co. LLC valued at public offering price of $875.00 per share (effective 2024-03-19).

“On March 19, 2024, Super Micro Computer, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Goldman Sachs & Co. LLC (the “Underwriter”), relating to an underwritten public offering (the “Offering”) of 2,000,000 shares (the “Firm Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), at a public offering price of $875.00 per share.”
IGC IGC Pharma, Inc.

IGC Pharma, Inc. entered into Sales Agreement with A.G.P./Alliance Global Partners valued at aggregate offering price subject to certain limitations on the amount of Common Stock that may be of (effective 2024-03-19).

“On March 19, 2024, IGC Pharma, Inc. (the “Company”) entered into a new Sales Agreement (the “Agreement”) with A.G.P./Alliance Global Partners (the “Agent”)”
TDG TransDigm Group INC

TransDigm Group INC amended Amendment No. 15, Loan Modification Agreement and Refinancing Facility Agreement with Goldman Sachs Bank USA, as administrative agent and collateral agent, and the lenders party thereto (effective 2024-03-22).

“AMENDMENT NO. 15, LOAN MODIFICATION AGREEMENT AND REFINANCING FACILITY AGREEMENT dated as of March 22, 2024, relating to the SECOND AMENDED AND RESTATED CREDIT AGREEMENT dated as of June 4, 2014”
YIELD10 BIOSCIENCE, INC.

YIELD10 BIOSCIENCE, INC. entered into warrant exercise agreements with certain existing institutional investors (effective 2024-03-22).

“On March 22, 2024, Yield10 Bioscience, Inc., a Delaware corporation (the “ Company ”), entered into warrant exercise agreements (the “ Agreements ”) with certain existing institutional investors”
YIELD10 BIOSCIENCE, INC.

YIELD10 BIOSCIENCE, INC. entered into Agreements with certain existing institutional investors (effective 2024-03-22).

“On March 22, 2024, Yield10 Bioscience, Inc., a Delaware corporation (the “ Company ”), entered into warrant exercise agreements (the “ Agreements ”) with certain existing institutional investors”
AGCO AGCO CORP /DE

AGCO CORP /DE entered into Senior Note Indenture and First Supplemental Indenture with HSBC Bank USA, National Association (as trustee) valued at $1,100,000,000 aggregate principal amount of 5.450% 2027 Notes and 5.800% 2034 Notes (effective 2024-03-21).

“The Notes were issued pursuant to the Senior Note Indenture, dated as of March 21, 2024 (the “Base Indenture”), among the Company, the Guarantors and HSBC Bank USA, National Association, as trustee (the “Trustee”), as amended and supplemented by the First Supplemental Indenture, dated as of March 21, 2024, among the Company, the Guarantors and the Trustee (the “First Supplemental Indenture” and together with the Base Indenture, the “Indenture”).”
AGCO AGCO CORP /DE

AGCO CORP /DE entered into Underwriting Agreement with Morgan Stanley & Co. LLC, J.P. Morgan Securities LLC, Rabo Securities USA, Inc. valued at $1,100,000,000 (aggregate $400,000,000 2027 Notes + $700,000,000 2034 Notes) (effective 2024-03-18).

“On March 21, 2024, AGCO Corporation (the “Company”) completed its underwritten public offering of (i) $400,000,000 aggregate principal amount of 5.450% Senior Notes due 2027 (the “2027 Notes”) and (ii) $700,000,000 aggregate principal amount of 5.800% Notes due 2034 (the “2034 Notes”, and together with the 2027 Notes, the “Notes”), pursuant to an Underwriting Agreement, dated as of March 18, 2024 (the “Underwriting Agreement”), among the Company, the Guarantors (as defined below) and Morgan Stanley & Co. LLC, J.P. Morgan Securities LLC and Rabo Securities USA, Inc., as representatives of the underwriters named in the Underwriting Agreement.”
CALY Callaway Golf Co

Callaway Golf Co amended First Amendment to Term Loan Agreement with Bank of America, N.A., as administrative agent and collateral agent valued at Amendment reduced interest rate by 0.50% per annum, removed 0.10% credit spread adjustment, reset pr (effective 2024-03-19).

“On March 19, 2024 (the “Amendment Date”), the Company and certain of its subsidiaries entered into an amendment to the Term Loan Agreement (the “First Amendment” and, the Term Loan Agreement as amended by the First Amendment, the “Amended Term Loan Agreement”), which, among other things, amends certain terms and provisions of the Term Loan Agreement, including, without limitation, to (a) reduce the interest rate applicable to the outstanding Term Loans under the Term Loan Facility by 0.50% per annum, (b) remove the 0.10% per annum credit spread adjustment applicable to Term Loans under the Term Loan Facility accruing interest at Term SOFR (as defined below), and (c) reset the prepayment premium applicable to the Term Loans, such that prepayments of the Term Loans occurring within six months after the Amendment Date in connection with a repricing transaction will be subject to a prepayment premium equal to 1.00% of the principal amount being prepaid, subject to certain customary excepti”
CRK COMSTOCK RESOURCES INC

COMSTOCK RESOURCES INC entered into Subscription Agreement with Jones Purchasers (Arkoma Drilling L.P. and Williston Drilling L.P.) valued at 12,500,000 shares of common stock for total consideration of approximately $100.5 million at $8.036 (effective 2024-03-20).

“On March 20, 2024, Comstock Resources, Inc. (the "Company") entered into a subscription agreement (the "Subscription Agreement") with each of Arkoma Drilling L.P., a Texas limited partnership ("Arkoma") and Williston Drilling L.P., a Texas limited partnership ("Williston" and, together with Arkoma, the "Jones Purchasers"), pursuant ‎to which the Jones Purchasers shall purchase, and the Company shall issue and sell to the Jones ‎Purchasers, in the aggregate, 12,500,000 shares of common stock, $0.50 par value per share of the Company (the "Common Stock") for total consideration of approximately ‎‎$100.5 million and at per share price of $8.036‎ (the "Transaction").”
BCG Binah Capital Group, Inc.

Binah Capital Group, Inc. amended Fifth Amendment to the Credit Agreement with Oak Street Funding LLC.

“At Closing, Wentworth and certain other borrowers entered into the Fifth Amendment to the Credit Agreement (the " Amendment ") with Oak Street”
BCG Binah Capital Group, Inc.

Binah Capital Group, Inc. entered into Warrant Assumption Agreement with Continental Stock Transfer & Trust Company, KWAC.

“Continental Stock Transfer & Trust Company (the " Transfer Agent "), KWAC and the Company entered into the Warrant Assumption and Assignment Agreement (the " Warrant Assumption Agreement "), pursuant to which, among other things, KWAC assigned to the Company all of KWAC's right, title and interest in and to, and the Company assumed all of KWAC's liabilities and obligations under the certain Warrant Agreement”
BCG Binah Capital Group, Inc.

Binah Capital Group, Inc. entered into Lock-Up Agreement with the Holders.

“the Company entered into that certain Lock-up Agreement with the Holders (the " Lock-Up Agreement "), pursuant to which, subject to certain exceptions, the Holders agreed to not transfer or make any announcement of any intention to effect a transfer”
BCG Binah Capital Group, Inc.

Binah Capital Group, Inc. entered into Registration Rights Agreement with the PIPE Investor, Wentworth, certain equity holders of Wentworth and certain other parties identified therein.

“the Company entered into that certain Registration Rights Agreement with the PIPE Investor, Wentworth, certain equity holders of Wentworth and certain other parties identified therein (such persons, the " Holders ") (the " Registration Rights Agreement ").”
BCG Binah Capital Group, Inc.

Binah Capital Group, Inc. entered into Subscription Agreement with Pollen Street Capital Limited valued at aggregate gross proceeds of $14,400,000.

“the Company and Wentworth entered into that certain Subscription Agreement (the " Subscription Agreement ") with Pollen Street Capital Limited (the " PIPE Investor "), pursuant to which, on the Closing Date, the PIPE Investor subscribed for and purchased, and the Company issued and sold to the PIPE Investor, an aggregate of 1,500,000 Series A Preferred Stock for a purchase price of $9.60 per share, for aggregate gross proceeds of $14,400,000 (the " PIPE Financing ").”
MLYS Mineralys Therapeutics, Inc.

Mineralys Therapeutics, Inc. entered into ATM Equity Offering Sales Agreement with BofA Securities, Inc. and Evercore Group L.L.C. valued at $100,000,000 (effective 2024-03-21).

“On March 21, 2024, Mineralys Therapeutics, Inc. (the “Company”), entered into an ATM Equity Offering Sales Agreement (the “Agreement”) with BofA Securities, Inc. and Evercore Group L.L.C. as the Company’s sales agents (the “Agents”) and/or principals. Pursuant to the terms of the Agreement, the Company may sell from time to time through the Agents shares of the Company’s common stock having an aggregate offering price of up to $100,000,000 (the “Shares”).”
Golub Capital BDC 4, Inc.

Golub Capital BDC 4, Inc. amended PNC Facility Amendment with PNC Bank, National Association (effective 2024-03-15).

“On March 15, 2024, Golub Capital BDC 4, Inc. (the “Company”) and Golub Capital BDC 4 Funding LLC (“GBDC 4 Funding”), a direct, wholly owned subsidiary of the Company, entered into an amendment (together with certain other documents executed concurrently, the “PNC Facility Amendment”)”
Presto Automation Inc.

Presto Automation Inc. amended Second Amendment with Presto CA LLC (effective 2024-03-21).

“On March 21, 2024, in connection with the issuance of the Note, the Company entered into a second amendment (the “Second Amendment”) to Purchase Agreement dated October 10, 2023, between the Company and Presto CA (the “CA Purchase Agreement”).”
Presto Automation Inc.

Presto Automation Inc. amended Seventh Amendment with Metropolitan Partners Group Administration, LLC (effective 2024-03-21).

“On March 21, 2024, the Company entered into a Seventh Amendment (the “Seventh Amendment”) to the Credit Agreement dated as of September 21, 2022 (as subsequently amended, the “Credit Agreement”) with the Agent for the Lenders.”
Presto Automation Inc.

Presto Automation Inc. entered into Secured Promissory Note with Presto CA LLC valued at $4,000,000 (effective 2024-03-21).

“On March 21, 2024, Presto Automation Inc. (“Presto” or the “Company”), together with Presto Automation, LLC, issued to Presto CA LLC (“Presto CA”) a secured promissory note in the principal amount of $4,000,000 (the “Note”), pursuant to which Presto CA agreed to make two loans totaling an aggregate of $4,000,000 to the Company.”
SPIR Spire Global, Inc.

Spire Global, Inc. entered into Placement Agent Agreement with A.G.P./Alliance Global Partners valued at Exclusive placement agent for the Offering, fee of 6% of gross proceeds and 4% of warrant exercise p (effective 2024-03-21).

“On March 21, 2024, the Company entered into a placement agency agreement (the “Placement Agent Agreement”) with A.G.P./Alliance Global Partners (“A.G.P.”) (the “Placement Agent”), pursuant to which the Company engaged A.G.P. as the exclusive placement agent in connection with the Offering.”
SPIR Spire Global, Inc.

Spire Global, Inc. entered into Securities Purchase Agreement with institutional investors valued at 2,142,858 shares of Class A Common Stock and warrants, aggregate gross proceeds of $30.0 million, of (effective 2024-03-21).

“On March 21, 2024, Spire Global, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with institutional investors (the “Investors”), pursuant to which the Company agreed to issue and sell, in a registered direct offering by the Company directly to the Investors (the “Offering”), (i) an aggregate of 2,142,858 shares (the “Shares”) of Class A Common Stock of the Company and (ii) warrants exercisable for an aggregate of 2,142,858 shares of Class A Common Stock (the “Warrants”) to the Investors.”
CSWC CAPITAL SOUTHWEST CORP

CAPITAL SOUTHWEST CORP entered into Loan Financing and Servicing Agreement with Deutsche Bank AG, New York Branch valued at $150 million initial commitments, increase to $200 million, accordion up to $400 million (effective 2024-03-20).

“On March 20, 2024, Capital Southwest Corporation (the “Company”) entered into a Loan Financing and Servicing Agreement (the “Loan Agreement”) for a special purpose vehicle financing credit facility (the “SPV Facility”) by and among Capital Southwest SPV LLC (“Capital Southwest SPV”), as borrower, the Company, as equityholder and servicer, Deutsche Bank AG, New York Branch (“Deutsche Bank”), as facility agent, U.S. Bank Trust Company, National Association as collateral agent, U.S. Bank National Association, as collateral custodian, and the lenders that are party thereto from time to time. The SPV Facility provides for $150 million of initial commitments with (i) an increase to $200 million of total commitments on the earlier of (a) June 20, 2024, the three month anniversary of the effective date of the Loan Agreement, or (b) the date requested by the Company, in its sole discretion, and (ii) an accordion feature that allows increases up to $400 million of total commitments from new and”
YYAI AIRWA INC.

AIRWA INC. entered into Share Exchange Agreement with Mr. Hongyu Zhou valued at $56 million (effective 2024-03-18).

“On March 18, 2024, Connexa Sports Technologies Inc. (the “ Company ”) entered into a share purchase agreement (the “ Share Purchase Agreement ”) and a share exchange agreement (the “ Share Exchange Agreement ,””
YYAI AIRWA INC.

AIRWA INC. entered into Share Purchase Agreement with Mr. Hongyu Zhou valued at $16,500,000 (effective 2024-03-18).

“On March 18, 2024, Connexa Sports Technologies Inc. (the “ Company ”) entered into a share purchase agreement (the “ Share Purchase Agreement ”)”
ShiftPixy, Inc.

ShiftPixy, Inc. amended Warrant Amendment with an investor (effective 2024-03-21).

“Effective upon closing of the Offering, pursuant to an amendment to common stock purchase warrants (the “Warrant Amendment”), the exercise price of an aggregate of 97,850 outstanding warrants the Company issued to an investor in July 2022 and July 2023 was reduced to $4.25 and the term of these warrants was extended such that they will expire on March 21, 2029.”
ShiftPixy, Inc.

ShiftPixy, Inc. amended Engagement Agreement with A.G.P./Alliance Global Partners (effective 2024-03-18).

“A.G.P./Alliance Global Partners acted as placement agent for the Offering and received a fee of 7% of the gross proceeds, and reimbursement of certain expenses, pursuant to an engagement agreement between the Company and AGP, dated January 8, 2024, as amended on March 18, 2024 (as amended, the “Engagement Agreement”).”
ShiftPixy, Inc.

ShiftPixy, Inc. entered into Purchase Agreement with an investor (effective 2024-03-19).

“On March 19, 2024, ShiftPixy, Inc. (the “Company”) priced a “reasonable best efforts” offering (the “Offering”) for the sale by the Company of an aggregate of 590,000 shares of common stock, 586,470 pre-funded warrants (the “Pre-funded Warrants”), and 1,176,470 common warrants (“Common Warrants”) pursuant to a securities purchase agreement with an investor (“Purchase Agreement”).”
AA Alcoa Corp

Alcoa Corp entered into Indenture with The Bank of New York Mellon Trust Company, N.A., as trustee valued at $750,000,000 aggregate principal amount of 7.125% senior notes due 2031 (effective 2024-03-21).

“On March 21, 2024, Alcoa Nederland Holding B.V. (the “Issuer”), a wholly-owned subsidiary of Alcoa Corporation (the “Company”), completed an offering (the “Offering”) of $750,000,000 aggregate principal amount of 7.125% senior notes due 2031 (the “notes”).”
USAC USA Compression Partners, LP

USA Compression Partners, LP entered into Indenture with Computershare Trust Company, N.A. valued at $1,000,000,000 in aggregate principal amount (effective 2024-03-18).

“of $1,000,000,000 in aggregate principal amount of the Issuers’ 7.125% senior notes due 2029 (the “Notes”), the Partnership entered into an Indenture (the “Indenture”), among the Issuers, the Guarantors”
AXIM AXIM BIOTECHNOLOGIES, INC.

AXIM BIOTECHNOLOGIES, INC. entered into a notes offering with its independent directors, certain officers and contractors of the Company, and employees of its wholly-owned subsidiary, Sapphire Biotech, Inc. valued at aggregate face value of $814,555 (effective 2024-03-15).

“On March 15, 2024, AXIM Biotechnologies, Inc. (the “Company”) issued Convertible Notes, having an aggregate face value of $814,555 (the "Notes"), to (i) its independent directors for past due director fees, (ii) certain officers and contractors of the Company for past due salaries and fees for services rendered, and (iii) employees of its wholly-owned subsidiary, Sapphire Biotech, Inc. ("Sapphire"), for past due salaries.”
ANVS Annovis Bio, Inc.

Annovis Bio, Inc. entered into Securities Purchase Agreement with an institutional investor valued at $3,000,000 (effective 2024-03-21).

“On March 21, 2024, Annovis Bio, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with an institutional investor (the “Buyer”).”
FATE FATE THERAPEUTICS INC

FATE THERAPEUTICS INC entered into Securities Purchase Agreement with a fund affiliated with Redmile Group, LLC valued at approximately $20.0 million (effective 2024-03-19).

“On March 19, 2024, the Company entered into a securities purchase agreement (the “Purchase Agreement”) with a fund affiliated with Redmile Group, LLC (collectively, “Redmile”).”
FATE FATE THERAPEUTICS INC

FATE THERAPEUTICS INC entered into Underwriting Agreement with BofA Securities, Inc., Jefferies LLC and Leerink Partners LLC valued at $74.7 million (effective 2024-03-19).

“On March 19, 2024, Fate Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with BofA Securities, Inc., Jefferies LLC and Leerink Partners LLC, as representatives of the several underwriters (the “Underwriters”), pursuant to which the Company agreed to issue and sell 14,545,454 shares of the Company’s common stock, par value $0.001 per share (the “Shares”), at an offering price of $5.50 per Share (the “Offering”).”
Motos America, Inc.

Motos America, Inc. entered into Membership Interest Purchase Agreement with New Start Financial, LLC (effective 2024-01-01).

“on January 1, 2024, the Company completed a Membership Interest Purchase Agreement to purchase 100% of the membership interests in a Utah limited liability company, New Start Financial, LLC (“New Start”).”
Motos America, Inc.

Motos America, Inc. entered into Asset Purchase Agreements with Hattar Motorcycles Inc., a California Corporation, dba Marin Speed Shop; NGCW Inc., a California Corporation, dba Scuderia West; Rockridge East Bay, LLC, a California Limited Liability Company, dba Rockridge Two Wheels; Cleveland Motor Holdings, LLC, a Washington Limited Liability Company, dba Trium (effective 2024-01-29).

“Additionally, the Company entered into asset purchase agreements (the "Asset Purchase Agreements") with the Counterparties to purchase the Dealerships in the future.”
Motos America, Inc.

Motos America, Inc. entered into Management Agreement with Hattar Motorcycles Inc., a California Corporation, dba Marin Speed Shop; NGCW Inc., a California Corporation, dba Scuderia West; Rockridge East Bay, LLC, a California Limited Liability Company, dba Rockridge Two Wheels; Cleveland Motor Holdings, LLC, a Washington Limited Liability Company, dba Trium (effective 2024-01-01).

“On January 1, 2024, Motos America Inc. (the "Company") entered into a material definitive agreement (the "Management Agreement") with Hattar Motorcycles Inc., a California Corporation, dba Marin Speed Shop; NGCW Inc., a California Corporation, dba Scuderia West; Rockridge East Bay, LLC, a California Limited Liability Company, dba Rockridge Two Wheels; Cleveland Motor Holdings, LLC, a Washington Limited Liability Company, dba Triumph of Seattle dba The Wick Coffee Shop; and Triumph Brooklyn, LLC, a New York Limited Liability Company, dba Triumph Brooklyn; (each individually, a “Counterparty” and collectively, the "Counterparties"), pursuant to which the Company shall provide management services for multiple motorcycle dealerships owned by the Counterparties (the "Dealerships").”
AQST Aquestive Therapeutics, Inc.

Aquestive Therapeutics, Inc. entered into Underwriting Agreement with Leerink Partners LLC and Piper Sandler & Co. valued at $69.8 million net proceeds (effective 2024-03-19).

“On March 19, 2024, Aquestive Therapeutics, Inc. (the "Company") entered into an underwriting agreement (the "Underwriting Agreement") by and among the Company and Leerink Partners LLC and Piper Sandler & Co., as representatives of the several underwriters named therein (the "Underwriters"), relating to an underwritten public offering of 16,666,667 shares of the Company's common stock, par value $0.001 per share ("Common Stock"), at a public offering price of $4.50 per share.”
OPTT Ocean Power Technologies, Inc.

Ocean Power Technologies, Inc. entered into Sales Agreement with A.G.P./Alliance Global Partners valued at up to $7,000,000 (effective 2024-03-21).

“On March 21, 2024, Ocean Power Technologies, Inc. (the “Company”) entered into a sales agreement with A.G.P./Alliance Global Partners (“A.G.P.”), pursuant to which the Company may offer and sell shares of its common stock, par value $0.001 per share (the “Common Stock”), having an aggregate offering price of up to $7,000,000 (the “Shares”), to or through A.G.P., as sales agent (the “Sales Agreement”), from time to time, in an “at the market offering””
FENC FENNEC PHARMACEUTICALS INC.

FENNEC PHARMACEUTICALS INC. entered into License and Supply Agreement with Norgine Pharma UK Limited valued at €40 million (effective 2024-03-15).

“On March 15, 2024, Fennec Pharmaceuticals, Inc., a Delaware corporation (“Fennec”) and wholly owned subsidiary of Fennec Pharmaceuticals Inc. (the “Company”), entered into a License and Supply Agreement (the “Agreement”) with Norgine Pharma UK Limited (“Norgine”)”
VOLKSWAGEN AUTO LEASE/LOAN UNDERWRITTEN FUNDING, LLC

VOLKSWAGEN AUTO LEASE/LOAN UNDERWRITTEN FUNDING, LLC entered into Underwriting Agreement with J.P. Morgan Securities LLC, on its own behalf and as representative of the several underwriters thereunder valued at aggregate principal balance of $1,500,000,000 (effective 2024-03-19).

“On March 19, 2024 , Volkswagen Auto Lease/Loan Underwritten Funding, LLC (“VALU Funding”), VW Credit, Inc. (“VCI”) and J.P. Morgan Securities LLC, on its own behalf and as representative of the several underwriters thereunder (the “Underwriters”) entered into an Underwriting Agreement, pursuant to which notes in the following classes: Class A-1, Class A-2-A, Class A-2-B, Class A-3 and Class A-4 (collectively, the “Notes”) with an aggregate principal balance of $1,500,000,000 were sold to the Underwriters.”
ECPG ENCORE CAPITAL GROUP INC

ENCORE CAPITAL GROUP INC entered into Indenture with GLAS Trust Company LLC as trustee and Truist Bank as security agent valued at $500.0 million aggregate principal amount (effective 2024-03-20).

“On March 20, 2024 , Encore Capital Group, Inc. (the “ Company ”) issued $500.0 million aggregate principal amount of 9.250% senior secured notes due 2029 (the “ Notes ”) pursuant to an indenture (the “Indenture”) between, among others, the Company, certain subsidiaries of the Company as guarantors, GLAS Trust Company LLC as trustee and Truist Bank as security agent.”
BAX BAXTER INTERNATIONAL INC

BAXTER INTERNATIONAL INC amended Euro Amendment with Baxter Healthcare SA and Baxter World Trade SRL, as Borrowers, their existing lender group, Baxter, as Guarantor, and J.P. Morgan SE, as Administrative Agent (effective 2024-03-21).

“On March 21, 2024, Baxter Healthcare SA and Baxter World Trade SRL, as Borrowers (the “ Euro Borrowers ”), their existing lender group, Baxter, as Guarantor, and J.P. Morgan SE, as Administrative Agent, entered into a third guaranty amendment (the “ Euro Amendment ”) to the existing amended and restated guaranty agreement, dated as of October 1, 2021”

Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.